Skip to content
OpenCapital
Get started

BioSig Technologies, Inc. STEX Cash, cash equivalents and short-term investments

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-61.8%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%—
Debt / equity0×—
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s cash, cash equivalents and short-term investments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s cash, cash equivalents and short-term investments?
BioSig Technologies, Inc. (STEX) reported cash, cash equivalents and short-term investments of $366K in Q2 2025.